Actavis : Actavis Launches Generic Viagra® in Europe as Patents Expire
ZUG, SWITZERLAND - June 24, 2013 - Actavis, Inc. (NYSE: ACT), a leading global
specialty pharmaceutical company, today announced that it has launched
Sildenafil Actavis 25 mg, 50 mg and 100 mg tablets in 11 major
Western-European markets on market formation. Sildenafil Actavis, the generic
equivalent of Pfizer's Viagra^®, is prescribed to treat erectile dysfunction.
Actavis' product was launched immediately after the patents expired in
Austria, Denmark, France, Germany, Ireland, Italy, The Netherlands, Spain,
Sweden, Switzerland and the United Kingdom.
Actavis first launched Sildenafil tablets in Bulgaria in June 2009 - the first
generic Sildenafil to enter the patent-free Bulgarian market - and has since
launched the product in various other patent-free markets in Europe, including
Iceland and Malta. Sildenafil Actavis is manufactured and developed by
Actavis, in Malta and Iceland respectively.
According to IMS Health, Viagra^® had sales of EUR382.2 million in Europe for
the 12 months ending March 31, 2013.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand
and biosimilar products. Actavis has global headquarters in Parsippany, New
Operating as Actavis Pharma, Actavis develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries.
Actavis Specialty Brands is Actavis' global branded specialty pharmaceutical
business focused in the Urology and Women's Health therapeutic categories.
Actavis Specialty Brands also has a portfolio of five biosimilar products in
development in Women's Health and Oncology. Actavis Global Operations has more
than 30 manufacturing and distribution facilities around the world, and
includes Anda, Inc., a U.S. pharmaceutical product distributor.
For press release and other company information, visit Actavis' Web site at
Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual
performance. Actual results may differ materially from Actavis' current
expectations depending upon a number of factors, risks and uncertainties
affecting Actavis' business. These factors include, among others, the impact
of competitive products and pricing; the timing and success of product
launches; difficulties or delays in manufacturing; the availability and
pricing of third party sourced products and materials; successful compliance
with governmental laws, rules and regulations applicable to Actavis and its
third party manufacturers' facilities, products and/or businesses; changes in
the laws and regulations affecting among other things, pricing and
reimbursement of pharmaceutical products; and such other risks and
uncertainties detailed in Actavis' periodic public filings with the Securities
and Exchange Commission, including but not limiting to Actavis' Quarterly
Report on Form 10-Q for the quarter ended March 31, 2013 and Actavis' annual
report on Form 10-K for the year ended December 31, 2012. Except as expressly
required by law, Actavis disclaims any intent or obligation to update these
Viagra^® is a registered trademark of Pfizer, Inc.
+1 862 261 7152
+41 79 909 7370
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Actavis via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.